New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase 2 trial of patients with relapsing multiple sclerosis.
